Skopos Labs, Inc. Verona Pharma PLC Transaction History
Skopos Labs, Inc.
- $453 Million
- Q1 2025
A detailed history of Skopos Labs, Inc. transactions in Verona Pharma PLC stock. As of the latest transaction made, Skopos Labs, Inc. holds 60 shares of VRNA stock, worth $5,005. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60
Previous 34
76.47%
Holding current value
$5,005
Previous $1,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$548 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$460 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$327 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$288 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$241 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $5.08B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...